(0.32%) 5 116.39 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.25%) $2.02
(0.30%) $2 354.20
(0.44%) $27.66
(4.16%) $960.50
(-0.26%) $0.932
(-0.47%) $10.97
(-0.57%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection...
Stats | |
---|---|
本日の出来高 | 36 392.00 |
平均出来高 | 50 070.00 |
時価総額 | 48.57M |
EPS | $0 ( 2024-03-31 ) |
次の収益日 | ( $0 ) 2024-06-03 |
Last Dividend | $0.0750 ( 2014-01-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.59 |
ATR14 | $0.0840 (3.11%) |
ボリューム 相関
XORTX Therapeutics Inc. 相関
10 最も負の相関 | |
---|---|
IDCC | -0.895 |
OTEX | -0.892 |
VBOCU | -0.89 |
BLBD | -0.888 |
MPRA | -0.887 |
OVLY | -0.887 |
NVCN | -0.887 |
GPACU | -0.886 |
OVID | -0.886 |
GRBK | -0.885 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
XORTX Therapeutics Inc. 相関 - 通貨/商品
XORTX Therapeutics Inc. 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.520 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
XORTX Therapeutics Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2011-08-10 |
Last Dividend | $0.0750 | 2014-01-31 |
Next Dividend | $0 | N/A |
Payout Date | 2014-02-17 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.795 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.171 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.972 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 9.15 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00429 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.22 | 2.00 | -1.741 | -3.48 | [0 - 30] |
freeCashFlowPerShareTTM | -5.25 | 2.00 | -2.63 | -5.25 | [0 - 20] |
debtEquityRatioTTM | 0.00468 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -366.22 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.285 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.753 | 1.000 | -0.177 | 0 | [1 - 100] |
returnOnEquityTTM | -0.972 | 2.50 | -7.65 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.25 | 2.00 | -1.751 | -5.25 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.22 | 2.00 | -1.741 | -3.48 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0129 | 1.500 | -3.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.45 |
XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。